Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.

@article{AbouElkacem2013RegorafenibIG,
  title={Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.},
  author={Lotfi Abou-Elkacem and Susanne Arns and Gunnar Brix and Felix Gremse and Dieter Zopf and Fabian Kiessling and Wiltrud Lederle},
  journal={Molecular cancer therapeutics},
  year={2013},
  volume={12 7},
  pages={1322-31}
}
The combination of target-specific drugs like bevacizumab with chemotherapeutics has improved treatment efficacy in advanced colorectal cancer (CRC). However, the clinical prognosis of metastatic CRCs is still poor, and novel drugs are currently assessed with respect to their efficacies in patients with CRCs. In a phase III study, the multikinase inhibitor regorafenib (BAY 73-4506) has recently been shown to prolong survival of patients with CRCs after standard therapies failed. In the present… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
38 Citations
61 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 61 references

Survival fromcolorectal cancer inGermany in the early 21st century

  • MajekO, A Gondos, L Jansen, K Emrich, B Holleczek, A Katalinic
  • Br J Cancer 2012;106:1875–80
  • 2012
Highly Influential
14 Excerpts

An update on the current and emerging targeted agents in metastatic colorectal cancer

  • E. Chu
  • Clin Colorectal Cancer
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…